BioMérieux’s New CE-Marked Mass Spectrometry System Makes Lab Life Easier During COVID-19 Pandemic
|
By LabMedica International staff writers Posted on 10 May 2021 |

Image: VITEK MS PRIME (Photo courtesy of BioMérieux)
BioMérieux (Marcy-l'Étoile, France) has announced the CE-marking of VITEK MS PRIME, the next generation of the VITEK MS MALDI-TOF1 mass spectrometry system for routine microbial identification in minutes that aims to make lab life easier during the COVID-19 pandemic.
Rapid microorganism identification is a pivotal step in the microbiology workflow. Over the past decade, Matrix-Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) mass spectrometry has transformed this process, providing critical information rapidly to clinicians in order to prescribe more effective antimicrobial therapy. Including time-saving innovations to deliver faster identification results, VITEK MS PRIME is a compact benchtop system designed to increase laboratory productivity for greater impact to patient care.
VITEK MS PRIME is a Matrix-Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) mass spectrometer that analyzes material from microbial cultures to provide microorganism identification. Samples are submitted to multiple laser shots inside VITEK MS PRIME. The matrix absorbs the laser light and vaporizes, along with the sample, in the process gaining an electrical charge (ionization). Electric fields then guide the ions into a vacuum tube which separates them according to their weight, with the smaller molecules rising up the column faster than the larger molecules. This “time of flight” creates a series of peaks, which correspond with the different molecules contained in the organism from the sample. All of these peaks create spectra unique to that microorganism. By comparing the spectra to a vast comprehensive library owned by bioMérieux, the precise microorganism can be identified quickly and easily. VITEK MS PRIME has been designed to incorporate additional benefits to further enhance the use of the MALDI-TOF technology.
With 700,0002 deaths worldwide annually, antimicrobial resistance (AMR) is a global health priority. Antimicrobial Stewardship (AMS), a key part of the arsenal to fight resistance, starts with diagnostics. VITEK MS PRIME positively impacts stewardship programs by providing even faster, highly accurate pathogen identification making excellent use of the large database of clinically relevant species to support earlier, targeted therapy.
“We had extensive input directly from labs as we developed VITEK MS PRIME,” said François Lacoste, Executive Vice President R&D. “The system incorporates numerous innovative features to make lab life easier, including improved automation and serviceability, with a robust database that is consistently expanding with new emerging pathogens and clinically relevant species. It integrates seamlessly with VITEK 2 for antimicrobial susceptibility testing and MYLA middleware for data integration and insights.”
“We are really pleased to bring this unique system to labs during the COVID-19 pandemic, when their needs for optimal workflow and efficiency are greater than ever,” said Pierre Boulud, Chief Operating Officer, Clinical Operations, “VITEK MS PRIME is a powerful innovation that reinforces our offer to support antimicrobial stewardship. Unique features like prioritization of urgent samples and continuous ‘load and go’ allow for greater efficiency and improved outcomes, which are also key in the fight against antimicrobial resistance.”
Related Links:
BioMérieux
Rapid microorganism identification is a pivotal step in the microbiology workflow. Over the past decade, Matrix-Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) mass spectrometry has transformed this process, providing critical information rapidly to clinicians in order to prescribe more effective antimicrobial therapy. Including time-saving innovations to deliver faster identification results, VITEK MS PRIME is a compact benchtop system designed to increase laboratory productivity for greater impact to patient care.
VITEK MS PRIME is a Matrix-Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) mass spectrometer that analyzes material from microbial cultures to provide microorganism identification. Samples are submitted to multiple laser shots inside VITEK MS PRIME. The matrix absorbs the laser light and vaporizes, along with the sample, in the process gaining an electrical charge (ionization). Electric fields then guide the ions into a vacuum tube which separates them according to their weight, with the smaller molecules rising up the column faster than the larger molecules. This “time of flight” creates a series of peaks, which correspond with the different molecules contained in the organism from the sample. All of these peaks create spectra unique to that microorganism. By comparing the spectra to a vast comprehensive library owned by bioMérieux, the precise microorganism can be identified quickly and easily. VITEK MS PRIME has been designed to incorporate additional benefits to further enhance the use of the MALDI-TOF technology.
With 700,0002 deaths worldwide annually, antimicrobial resistance (AMR) is a global health priority. Antimicrobial Stewardship (AMS), a key part of the arsenal to fight resistance, starts with diagnostics. VITEK MS PRIME positively impacts stewardship programs by providing even faster, highly accurate pathogen identification making excellent use of the large database of clinically relevant species to support earlier, targeted therapy.
“We had extensive input directly from labs as we developed VITEK MS PRIME,” said François Lacoste, Executive Vice President R&D. “The system incorporates numerous innovative features to make lab life easier, including improved automation and serviceability, with a robust database that is consistently expanding with new emerging pathogens and clinically relevant species. It integrates seamlessly with VITEK 2 for antimicrobial susceptibility testing and MYLA middleware for data integration and insights.”
“We are really pleased to bring this unique system to labs during the COVID-19 pandemic, when their needs for optimal workflow and efficiency are greater than ever,” said Pierre Boulud, Chief Operating Officer, Clinical Operations, “VITEK MS PRIME is a powerful innovation that reinforces our offer to support antimicrobial stewardship. Unique features like prioritization of urgent samples and continuous ‘load and go’ allow for greater efficiency and improved outcomes, which are also key in the fight against antimicrobial resistance.”
Related Links:
BioMérieux
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more
FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
Accurate evaluation of androgen status often requires concordant measurement of total testosterone, free testosterone, and sex hormone‑binding globulin. Reference methods such as equilibrium dialysis with... Read moreMolecular Diagnostics
view channel
Realistic Mock Samples Aim to Speed Cervical Cancer Test Development
Cervical cancer remains highly preventable, yet screening access is limited in many low- and middle-income settings. Gold-standard tests for high-risk human papillomavirus (HPV) detect viral DNA or messenger... Read more
Molecular Marker Identifies Hormone Therapy Resistance Pathway in Prostate Cancer
Most prostate cancers depend on androgen signaling, making hormone suppression or blockade a central treatment strategy. Although many patients respond initially, tumors often adapt and eventually progress,... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read moreMicrobiology
view channel
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more









